Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose-response efficacy

Journal of Controlled Release

Volumn 210, Issue , 2015, Pages 19-25

  Vong, Long Binh ^a   Mo, John ^b   Abrahamsson, Bertil ^b   Nagasaki, Yukio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Antioxidant therapy; Inflammation; Oral drug delivery; Reactive oxygen species; Redox nanoparticles; Ulcerative colitis

Indexed keywords

CELLS; CYTOLOGY; DISEASES; MAMMALS; MOBILE SECURITY; NANOPARTICLES; OXYGEN; PATHOLOGY; SODIUM SULFATE;

ANTIOXIDANT THERAPIES; INFLAMMATION; ORAL DRUG DELIVERY; REACTIVE OXYGEN SPECIES; ULCERATIVE COLITIS;

DISEASE CONTROL;

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; INTERLEUKIN 1BETA; MACROGOL; MESALAZINE; NANOPARTICLE; REACTIVE OXYGEN METABOLITE; REDOX NANOPARTICLE; RHODAMINE; UNCLASSIFIED DRUG; CALGRANULIN; DEXTRAN SULFATE; HYDROGEN PEROXIDE; INTERLEUKIN 8; OXIDIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; ELECTRON SPIN RESONANCE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTESTINE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; ULCERATIVE COLITIS; ANIMAL; CACO 2 CELL LINE; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; COLON; DRUG EFFECTS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; PATHOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CACO-2 CELLS; COLITIS, ULCERATIVE; COLON; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-8; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; OXIDANTS; OXIDATION-REDUCTION;

EID: 84929650203     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.05.275     Document Type: Article

References (26)

1. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nat. Rev. 474 2011 307 317
2. D.K. Podolsky Inflammatory bowel disease N. Engl. J. Med. 347 2002 417 429
3. C. Abraham, and H.J. Cho Mechanism of disease inflammatory bowel disease N. Engl. J. Med. 361 2009 2066 2078
4. V.L. Edward Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences Gastroenterology 126 2004 1504 1517
5. N.J. Simmonds, and D.S. Rampton Inflammatory bowel disease a radical view Gut 34 1993 865 868
6. R.J. Xavier, and D.K. Podolsky Unravelling the pathogenesis of inflammatory bowel disease Nat. Rev. 448 2007 427 434
7. C.F. Babbs Oxygen radicals in ulcerative colitis Free Radic. Biol. Med. 13 1992 169 182
8. J.M. McCord The evolution of free radicals and oxidative stress Am. J. Med. 108 2000 652 659
9. C. Mowat, A. Cole, A. Windsor, T. Ahmad, I. Arnott, R. Driscoll, S. Mitton, T. Orchard, M. Rutter, L. Younge, C. Lees, G.T. Ho, J. Satsangi, and S. Bloom Guidelines for the management of inflammatory bowel disease in adults Gut 60 2011 571 607
10. J.K. Triantafillidis, E. Merikas, and F. Georgopoulos Current and emerging drugs for the treatment of inflammatory bowel disease Drug Des. Dev. Ther. 5 2011 85 210
11. L.B. Vong, T. Tomita, T. Yoshitomi, H. Matsui, and Y. Nagasaki An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice Gastroenterology 143 2012 (1027-1036.e3)
12. L.B. Vong, T. Yoshitomi, K. Morikawa, S. Saito, H. Matsui, and Y. Nagasaki Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis J. Gastroenterol. 49 2014 806 813
13. T. Yoshitomi, R. Suzuki, T. Mamiya, H. Matsui, A. Hirayama, and Y. Nagasaki pH-sensitive radical-containing-nanoparticle (RNP) for the L-band-EPR imaging of low pH circumstances Bioconjug. Chem. 20 2009 1792 1798
14. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740
15. H.S. Cooper, S.N. Murthy, R.S. Shah, and D.J. Sedergran Clinicopathologic study of dextran sulfate sodium experimental murine colitis Lab. Invest. 69 1993 238 249
16. S.S. Wijeratne, S.L. Cuppett, and V. Schlegel Hydrogen peroxide induced oxidative stress damage and antioxidant enzyme response in Caco-2 human colon cells J. Agric. Food Chem. 53 2005 8768 8774
17. Y. Nagasaki Nitroxide radicals and nanoparticles: a partnership for nanomedicine radical delivery Ther. Deliv. 3 2012 165 179
18. H.Y. Hsu, and M.H. Wen Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression J. Biol. Chem. 277 2002 22131 22139
19. C.A. Dinarello Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 2011 3720 37032
20. M. Tobio, A. Sanchez, A. Vila, I. Soriano, C. Evora, J.L. Vila-Jato, and M.J. Alonso The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration Colloids Surf. B 18 2000 315 323
21. S.K. Lai, Y.Y. Wang, and J. Hanes Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues Adv. Drug Deliv. Rev. 61 2009 158 171
22. L.M. Ensign, R. Cone, and J. Hanes Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers Adv. Drug Deliv. Rev. 64 2012 557 570
23. R.D. Pullan, G. Thomas, M. Rhodes, R.G. Newcombe, G.T. Williams, A. Allen, and J. Rhodes Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis Gut 35 1994 353 359
24. M.E. Johansson, H. Sjovall, and G.C. Hansson The gastrointestinal mucus system in health and disease Nat. Rev. Gastroenterol. Hepatol. 10 2013 352 361
25. L.B. Vong, T. Yoshitomi, H. Matsui, and Y. Nagasaki Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer Biomaterials 55 2015 54 63
26. N.M. Davies Sustained release and enteric coated NSAIDs: are they really GI safe? J. Pharm. Pharm. Sci. 2 1999 5 14